STOCK TITAN

Disc Medicine to Participate in Upcoming Investor Conferences

Disc Medicine (NASDAQ:IRON), a clinical-stage biopharmaceutical company specializing in treatments for hematologic diseases, has announced its participation in two major investor conferences.

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Disc Medicine (NASDAQ:IRON), a clinical-stage biopharmaceutical company specializing in treatments for hematologic diseases, has announced its participation in two major investor conferences. The company's management will engage in fireside chats at the Jefferies Global Healthcare Conference on June 5th at 10:30 a.m. ET and the Goldman Sachs 46th Annual Global Healthcare Conference on June 9th at 1:20 p.m. ET. Both sessions will be accessible via live webcast through Disc Medicine's investor relations website, with archived replays available post-event.

Loading...
Loading translation...
Argus Session date unavailable
+3.88% session move Open Argus
Details

News Market Reaction – IRON

The recorded move for IRON in the trading session of this news was +3.88%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

WATERTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at two upcoming investor conferences:

  • Jefferies Global Healthcare Conference on Thursday, June 5th at 10:30 a.m. ET.

  • Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9th at 1:20 p.m. ET.

Live webcasts of the fireside chats will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available after the event.

About Disc Medicine

Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.

Media Contact

Peg Rusconi
Deerfield Group
peg.rusconi@deerfieldgroup.com

Investor Relations Contact

Christina Tartaglia
Precision AQ
christina.tartaglia@precisionaq.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Disc Medicine (IRON) presenting at the Jefferies Global Healthcare Conference 2025?

Disc Medicine will present at the Jefferies Global Healthcare Conference on Thursday, June 5th, 2025, at 10:30 a.m. ET.

What time is IRON's presentation at the Goldman Sachs Healthcare Conference 2025?

Disc Medicine will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9th, 2025, at 1:20 p.m. ET.

How can investors watch Disc Medicine's (IRON) conference presentations?

Investors can watch the live webcasts through Disc Medicine's investor relations website at ir.discmedicine.com. Archived replays will also be available after the events.

What is Disc Medicine's (IRON) main business focus?

Disc Medicine is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel treatments for patients with serious hematologic diseases.

Keep reading